VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Dr. Palmerini on Long-term Efficacy of Denosumab in Giant Cell Tumor of Bone

Emanuela Palmerini, MD
Published: Saturday, Sep 09, 2017



Emanuela Palmerini, MD, Prometeo Laboratory: Clinical and Experimental Research Contract, Chemotherapy for Rare Musculoskeletal Tumors Department, Rizzoli Orthopaedic Institute, discusses the long-term efficacy of denosumab (Xgeva) in patients with giant cell tumor of bone (GCTB).

The phase II study enrolled more than 500 patients with GCTB, which is defined as a progressive osteolytic tumor, in 3 cohorts: unresectable disease (cohort 1), resectable disease with planned high morbidity surgery (cohort 2), and prior GCTB study patients (cohort 3). Patients were treated with subcutaneous denosumab, which is a monoclonal antibody, at 120 mg every 4 weeks with loading doses on days 8 and 15. With a primary endpoint of safety and progression-free survival, results showed that the drug was able to safely control the disease in all patients with metastatic or unresectable disease.

The overall response rates in cohorts 1 and 2 were both 99%. The recurrence risk was 27% following surgery in those patients with high-risk resectable disease. 

  <<< View more from the 2017 ESMO Congress
 


Emanuela Palmerini, MD, Prometeo Laboratory: Clinical and Experimental Research Contract, Chemotherapy for Rare Musculoskeletal Tumors Department, Rizzoli Orthopaedic Institute, discusses the long-term efficacy of denosumab (Xgeva) in patients with giant cell tumor of bone (GCTB).

The phase II study enrolled more than 500 patients with GCTB, which is defined as a progressive osteolytic tumor, in 3 cohorts: unresectable disease (cohort 1), resectable disease with planned high morbidity surgery (cohort 2), and prior GCTB study patients (cohort 3). Patients were treated with subcutaneous denosumab, which is a monoclonal antibody, at 120 mg every 4 weeks with loading doses on days 8 and 15. With a primary endpoint of safety and progression-free survival, results showed that the drug was able to safely control the disease in all patients with metastatic or unresectable disease.

The overall response rates in cohorts 1 and 2 were both 99%. The recurrence risk was 27% following surgery in those patients with high-risk resectable disease. 

  <<< View more from the 2017 ESMO Congress
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x